» Articles » PMID: 8690406

Interferon Gamma Down-regulates Cytochrome P450 3A Genes in Primary Cultures of Well-differentiated Rat Hepatocytes

Overview
Journal Hepatology
Specialty Gastroenterology
Date 1996 Aug 1
PMID 8690406
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Administration of interferons of both the gamma and alfa/beta classes down-regulates hepatic cytochrome P450 (CYP) genes when administered to humans or rats. In male rats, interferons decrease expression of CYP3A2 at a pretranslational level, but because interferons also release other cytokines in vivo, it is unclear whether this is a direct effect on hepatocytes. We therefore examined the effects of rat recombinant interferon gamma (IFN-gamma) on CYP3A2, other 3A genes, and 2C11 in stable primary cultures of male rat hepatocytes. Hepatocytes were cultured on matrigel in Williams' E, and messenger RNAs (mRNAs) for 3A2, 3A1-like CYPs, and 2C11 mRNA were determined by RNase protection assays. CYP3A and 2C11 proteins were immunoquantified, and their catalytic activities were estimated by testosterone hydroxylation pathways. In control cells, 3A2 mRNA decreased initially but then recovered, and stable levels (15% of freshly isolated cells) were attained between days 3 and 7. Phenobarbital increased 3A2 mRNA to 60-120% values of freshly isolated cells, and mRNA for 3A1-like CYPs were increased 20-fold. In both control and phenobarbital-treated hepatocytes, rat recombinant IFN-gamma (33 U/mL) reduced mRNA for 3A2 and 3A1-like CYPs, as well as 3A protein and testosterone 6 beta-hydroxylase activity. Interferon had no effect on CYP2C11 at mRNA or protein levels in untreated cells, although a reduction in 2C11 protein was evident in phenobarbital-treated cultures. It is concluded that interferon directly alters expression of constitutive and inducible CYP3A genes in well-differentiated male rat hepatocytes in culture, but has no effect on constitutive expression of CYP2C11.

Citing Articles

The Role of Cytochrome P450 Enzymes in COVID-19 Pathogenesis and Therapy.

Wang G, Xiao B, Deng J, Gong L, Li Y, Li J Front Pharmacol. 2022; 13:791922.

PMID: 35185562 PMC: 8847594. DOI: 10.3389/fphar.2022.791922.


Frequently Asked Questions in Patients With Adrenal Insufficiency in the Time of COVID-19.

Sabbadin C, Betterle C, Scaroni C, Ceccato F Front Endocrinol (Lausanne). 2022; 12:805647.

PMID: 35002978 PMC: 8739913. DOI: 10.3389/fendo.2021.805647.


Disease-drug and drug-drug interaction in COVID-19: Risk and assessment.

Kumar D, Trivedi N Biomed Pharmacother. 2021; 139:111642.

PMID: 33940506 PMC: 8078916. DOI: 10.1016/j.biopha.2021.111642.


What we have to know about corticosteroids use during Sars-Cov-2 infection.

Ferrau F, Ceccato F, Cannavo S, Scaroni C J Endocrinol Invest. 2020; 44(4):693-701.

PMID: 32860209 PMC: 7454136. DOI: 10.1007/s40618-020-01384-5.


Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms.

El-Ghiaty M, Shoieb S, El-Kadi A Med Hypotheses. 2020; 144:110033.

PMID: 32758877 PMC: 7318945. DOI: 10.1016/j.mehy.2020.110033.